

Initial Seracam® characterization results presented at BNMS Spring Meeting, Harrogate

London, UK, 22 May 2023. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma/optical camera for medical imaging, announces that an abstract titled ‘Initial characterization of the Seracam: a small-footprint gamma-optical camera, with fully automated collimator changing capabilities’ is being presented in a poster presentation at the British Nuclear Medicine Society (BNMS) Spring meeting taking place from 22-24 May 2023, in Harrogate, UK.

The characterization results demonstrate that the gamma-imaging performance of Seracam®, in aspects such as spatial resolution, spatial linearity and uniformity values, exceeds that of large field of view cameras. The full results can be seen in the poster [here](#).

Professor Alan Perkins, one of the original developers of Seracam®, Scientific Advisor for Serac Imaging Systems and a former President of the BNMS, said:

“Seracam has come so far from its original conception which was based on technology developed for satellites to image distant stars, to offering a real step change in the development of small field of view gamma-optical camera systems. These results represent a great foundation for clinical testing, which will now assess the impact of the device’s novel features: its flexibility, mobility and hybrid-imaging capabilities.”

Mark Rosser, Chief Executive Officer of Serac Imaging Systems, said:

“These successful results from the characterization of Seracam’s imaging performance represent a critical and significant step forward in its development. By successfully miniaturising the planar functionality of large field of view gamma cameras, this new technology has the potential to extend the benefits of nuclear imaging to new patient groups in new locations, as well as improving workflows in the nuclear medicine department. We are now looking forward to confirming its performance in a clinical setting.”

About Seracam®

Seracam® is an innovative, compact and highly portable hybrid optical/gamma camera which is in development to bring the benefits of high-resolution molecular imaging to a patient’s bedside. This breakthrough technology will enable users to see the uptake of targeted tracers, labelled with minute amounts of radioactivity, to patients in a wide range of settings: an operating room, an intensive care unit, or a physician’s office. Currently the benefits of such imaging are largely confined to patients who can be referred to a hospital’s nuclear medicine department where the large, heavy and expensive conventional gamma cameras are sited in a fixed position in a dedicated room.

A further unique feature of Seracam®, is the combination of a gamma image overlaid with a co-aligned optical image of the same region of interest. This adds further information regarding the precise anatomical location of the molecular imaging tracer and could be used to aid the discussion between the physician and patient regarding their condition and the optimal treatment path.

Results from clinical testing using Seracam® will be available later this year.

- ENDS -

For more information, please contact:

Serac Imaging Systems Ltd

www.seracimagingsystems.com

Mark Rosser, Chief Executive Officer

+44 (0)208 948 0000

info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010 820

francettacarr@seraclifesciences.com

Notes to Editors

About Serac Imaging Systems

Serac Imaging Systems Ltd is the medtech company developing a portable hybrid gamma/optical camera for medical imaging. Our lead product is Seracam[®] which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions. Seracam[®] is a UK and EU registered trademark.

Seracam[®] is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see www.seracimaging.com

About molecular imaging

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.